Treatment and outcomes of paediatric patients
| Type of RMD | Age/gender | Comorbidities including BMI | RMD treatment | Outpatient management (Y/N) | COVID-19 treatment | COVID outcome | Other comments | SARS-CoV-2 PCR/serology | ||
| Corticosteroid | DMARD | |||||||||
| Pt 1 | Autoimmune bullous dermatosis | 4/F | Asthma/17 | IgIV, RITU | Y: increase of IgIV dosage | 0 | Benign | PCR+ | ||
| Pt 2 | Non-systemic JIA | 17/M | None/NA | NSAID, MTX, ADA | Y: stop NSAID, MTX and ADA | 0 | Benign | ND | ||
| Pt 3 | Non-systemic JIA | 7/F | None/14 | MTX, ADA | Y: stop ADA and MTX | 0 | Benign | Relapse of the JIA, recurrent herpes labialis | ND | |
| Pt 4 | Non-systemic JIA | 14/M | None/18 | N | 0 | Benign | Herpes zoster recurrence | ND | ||
| Pt 5 | FMF | 17/F | None/21 | Colchicine | N | 0 | Benign | Serology+ | ||
| Pt 6 | FMF | 16/M | None/23 | Colchicine, ADA | N | 0 | Moderate | PCR+ | ||
| Pt 7 | Systemic–onset JIA | 16/F | Smoking/22 | TOCI | Y: stop TOCI | 0 | Benign | Anaemia | PCR+ | |
| Pt 8 | SLE | 17/F | Smoking; obesity/45 | Hydroxychloroquine | N | 0 | Benign | Joint relapse | PCR+ | |
| Pt 9 | Sarcoidosis and uveitis | 13/F | None/20 | Prednisone 20 mg/day | N | 0 | Benign | Relapse of orbital pain | PCR+ | |
| Pt 10 | Non-systemic JIA | 16/M | None/22 | NSAID, MTX, ETA | Y: stop NSAID | 0 | Benign | PCR− | ||
| Pt 11 | Non-systemic JIA | 12/M | None/23 | N | 0 | Benign | ND | |||
| Pt 12 | Non-systemic JIA | 11/M | None/16 | ETA | N | 0 | Benign | ND | ||
| Pt 13 | Cryopyrinopathy | 9/M | None/21 | N | 0 | Benign | ND | |||
ADA, adalimumab; BMI, body mass index; DMARD, disease-modifying anti-rheumatic drug; ETA, etanercept; FMF, familial Mediterranean fever; IgIV, immunoglobulin intravenous; JIA, juvenile idiopathic arthritis; MTX, methotrexate; NA, not applicable; ND, not detected; NSAID, non-steroidal anti-inflammatory drug; RITU, rituximab; RMD, rheumatic and musculoskeletal diseases; SLE, systemic lupus erythematosus; TOCI, tocilizumab.